Mocht u de informatie op onze website waarderen dan wilt u ons misschien ondersteunen met een donatie?  Ons rekeningnummer is: RABO t.n.v. Stichting Gezondheid Actueel in Terneuzen.

Onze IBANcode is NL79 RABO 0372 9311 38

Als donateur kunt u ook korting krijgen bij verschillende bedrijven. En we hebben een ANBI status

23 mei 2020: recent is ook een reviewstudie over hyperthermie bij kanker met solide tumoren gepubliceerd die interessante informatie geeft met veel verwijzingen naar studies. Teveel om hier allemaal te noemen:

23 mei 2020: Bron: Journal of Advanced Research maart 2020

Hyperthermie (electro hyperthermie) samen met een intraveneuze behandeling met hoge dosis vitamine C (IVC)  verbetert de overall overleving met 40 procent van patiënten met vergevorderde voorbehandelde niet-kleincellige longkanker (NSCLC) in vergelijking met beste zorg.

Dit blijkt uit een studie met totaal 97 patiënten met niet-kleincellige longkanker stadium III/IV. Alle patiënten hadden al verschillende andere behandleingen gehad en waren op moment van starten met deze aanpak in principe onbehandelbaar en in vergevorderd stadium van hun ziekte. Een groep van 48 patiënten kreeg de combinatie therapie van hyperthermie en intraveneus vitamine C plus beste zorg, een groep van 47 patiënten alleen beste zorg. Ziektestadium en en lichamelijke en geestelijke gesteldheid was in beide groepen gelijk. Zie (Table 1).

Na een mediane follow-up van 24 maanden waren de progressievrije overleving (PFS) en de algehele overleving (OS) veel beter door de combinatietherapie van hyperthermie plus vitamine C per infuus naast beste zorg vergeleken met alleen beste zorg.
Het verschil in mediane overall overleving was maar liefst ca. 40 procent beter voor de combinatiegroep (OS: 9,4 maanden vs. 5,6 maanden, P <0,05). De kwaliteit van leven was ook veel beter in de combinatiegroep ondanks het gevorderde ziektestadium. De ziektecontrole (stabiele ziekte) na 3 maanden na start van de behandeling was 42,9% in de combinatiegroep van hyperthermie en vitamine C en 16,7% in de controlegroep van alleen beste zorg (P <0,05). 

Het volledige studierapport: A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer is gratis in te zien.

Hiert het abstract van de studie met referentielijst.

intravenous vitamin C (IVC) + modulated electrohyperthermia (mEHT) is well tolerated, significantly improves QoL, prolongs PFS and OS, and moderates cancer-related inflammation, so it is a feasible treatment in advanced NSCLC.

. 2020 Jul; 24: 175–182.
Published online 2020 Mar 17. doi: 10.1016/j.jare.2020.03.004
PMCID: PMC7190757
PMID: 32368355

A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer

An external file that holds a picture, illustration, etc.
Object name is ga1.jpgGraphical abstract


Our previous study indicated that intravenous vitamin C (IVC) treatment concurrent with modulated electrohyperthermia (mEHT) was safe and improved the quality of life (QoL) of non-small-cell lung cancer (NSCLC) patients. The aim of this trial was to further verify the efficacy of the above combination therapy in previously treated patients with refractory advanced (stage IIIb or IV) NSCLC. A total of 97 patients were randomized to receive IVC and mEHT plus best supportive care (BSC) (n = 49 in the active arm, receiving 1 g/kg * d IVC concurrently with mEHT, three times a week for 25 treatments in total) or BSC alone (n = 48 in the control arm). After a median follow-up of 24 months, progression-free survival (PFS) and overall survival (OS) were significantly prolonged by combination therapy compared to BSC alone (PFS: 3 months vs 1.85 months, P < 0.05; OS: 9.4 months vs 5.6 months, P < 0.05). QoL was significantly increased in the active arm despite the advanced stage of disease. The 3-month disease control rate after treatment was 42.9% in the active arm and 16.7% in the control arm (P < 0.05). Overall, IVC and mEHT may have the ability to improve the prognosis of patients with advanced NSCLC.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.


The authors sincerely thank the patients and investigators.

The study was financed with institutional funds from Clifford L.K. Pang Funding, China [Grant number: 2016-01], and the Major Medical and Health Project of the Department of Science, Technology, Industry, Commerce and Information Bureau in Panyu of Guangzhou [Grant number: 2018-Z04-05].

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.


Peer review under responsibility of Cairo University.

Appendix ASupplementary data to this article can be found online at

Appendix A. Supplementary material

The following are the Supplementary data to this article:

Supplementary data 1:


1. Chen W., Zheng R., Baade P.D., Zhang S., Zeng H., Bray F. Cancer statistics in China 2015. CA Cancer J Clin. 2016;66(2):115–132. [PubMed[]
2. Chen W., Zheng R., Zeng H., Zhang S. Epidemiology of lung cancer in China. Thorac Cancer. 2015;6(2):209–215. [PMC free article] [PubMed[]
3. Shenoy N., Creagan E., Witzig T., Levine M. Ascorbic acid in cancer treatment: let the phoenix fly. Cancer Cell. 2018;34(5):700–706. [PMC free article] [PubMed[]
4. Welsh J.L., Wagner B.A., van’t Erve T.J., Zehr P.S., Berg D.J., Halfdanarson T.R. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013;71(3):765–775. [PMC free article] [PubMed[]
5. Levine M., Wang Y., Padayatty S.J., Morrow J. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci U S A. 2001;98(17):9842–9846. [PMC free article] [PubMed[]
6. Creagan E.T., Moertel C.G., O'Fallon J.R., Schutt A.J., O'Connell M.J., Rubin J. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med. 1979;301(13):687–690. [PubMed[]
7. Stephenson C.M., Levin R.D., Spector T., Lis C.G. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;72(1):139–146. [PMC free article] [PubMed[]
8. Riordan H.D., Casciari J.J., Gonzalez M.J., Riodan N.H., Miranda-Massari J.R., Taylor P. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J. 2005;24(4):269–276. [PubMed[]
9. Ma Y., Chapman J., Levine M., Polireddy K., Drisko J., Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014;6(222):222ra18. [PubMed[]
10. Vollbracht C., Schneider B., Leendert V., Weiss G., Auerbach L., Beuth J. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. Vivo. 2011;25(6):983–990. [PubMed[]
11. Chen Q., Espey M.G., Sun A.Y., Pooput C., Kirk K.L., Krishna M.C. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A. 2008;105(32):11105–11109. [PMC free article] [PubMed[]
12. Chen Q., Espey M.G., Krishna M.C., Mitchell J.B., Corpe C.P., Buettner G.R. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A. 2005;102(38):13604–13609. [PMC free article] [PubMed[]
13. Carosio R., Zuccari G., Orienti I., Mangraviti S., Montaldo P.G. Sodium ascorbate induces apoptosis in neuroblastoma cell lines by interfering with iron uptake. Mol Cancer. 2007;6:55. [PMC free article] [PubMed[]
14. Schoenfeld J.D., Sibenaller Z.A., Mapuskar K.A., Wagner B.A., Cramer-Morales K.L., Furqan M. O2(−) and H2O2 mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate. Cancer Cell. 2017;32(2):268. [PubMed[]
15. Soares P.I., Ferreira I.M., Igreja R.A., Novo C.M., Borges J.P. Application of hyperthermia for cancer treatment: recent patents review. Recent Pat Anticancer Drug Discov. 2012;7(1):64–73. [PubMed[]
16. Cheng Y., Weng S., Yu L., Zhu N., Yang M., Yuan Y. The role of hyperthermia in the multidisciplinary treatment of malignant tumors. Integr Cancer Ther. 2019;18 1534735419876345. [PMC free article] [PubMed[]
17. Ohguri T., Imada H., Yahara K., Moon S.D., Yamaguchi S., Yatera K. Re-irradiation plus regional hyperthermia for recurrent non-small cell lung cancer: a potential modality for inducing long-term survival in selected patients. Lung Cancer. 2012;77(1):140–145. [PubMed[]
18. Szasz A.M., Minnaar C.A., Szentmártoni G., Szigeti G.P., Dank M. Review of the clinical evidences of modulated electro-hyperthermia (mEHT) method: an update for the practicing oncologist. Front Oncol. 2019;9:1012. [PMC free article] [PubMed[]
19. Andocs G., Renner H., Balogh L., Fonyad L., Jakab C., Szasz A. Strong synergy of heat and modulated electro-magnetic field in tumor cell killing. Strahlenther Onkol. 2009;185:120–126. [PubMed[]
20. Andocs G., Rehman M.U., Zhao Q.L., Papp E., Kondo T., Szasz A. Nanoheating without artificial nanoparticles part II. Experimental support of the nanoheating concept of the modulated electro-hyperthermia method, using U937 cell suspension model. Biol Med (Aligarh) 2015;7:1–9. []
21. Yang K.L., Huang C.C., Chi M.S., Chiang H.C., Wang Y.S., Hsia C.C. In vitro comparison of conventional hyperthermia and modulated electro-hyperthermia. Oncotarget. 2016;7(51):84082–84092. [PMC free article] [PubMed[]
22. Lee S.Y., Kim J.H., Han Y.H., Cho D.H. The effect of modulated electro-hyperthermia on temperature and blood flow in human cervical carcinoma. Int J Hyperthermia. 2018;34(7):953–960. [PubMed[]
23. Vancsik T., Kovago C., Kiss E., Papp E., Forika G., Benyo Z. Modulated electro-hyperthermia induced loco-regional and systemic tumor destruction in colorectal cancer allografts. J Cancer. 2018;9(1):41–53. [PMC free article] [PubMed[]
24. Yeo S.G. Definitive radiotherapy with concurrent oncothermia for stage IIIB non-small-cell lung cancer: a case report. Exp Ther Med. 2015;10(2):769–772. [PMC free article] [PubMed[]
25. Rubovszky G., Nagy T., Godeny M., Szasz A., Lang I. Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia. Pathol Oncol Res. 2013;19(1):119–122. [PubMed[]
26. Szasz A. Current status of oncothermia therapy for lung cancer. Korean J Thorac Cardiovasc Surg. 2014;47(2):77–93. [PMC free article] [PubMed[]
27. Ariyafar T., Mahdavi S.R., Geraily G., Fadavi P., Farhood B., Najafi M. Evaluating the effectiveness of combined radiotherapy and hyperthermia or the treatmentresponse of patients with painful bony metastases: a phase 2 clinical trial. J Therm Biol. 2019;84:129–135. [PubMed[]
28. Issels R.D., Lindner L.H., Verweij J., Wessalowski R., Reichardt P., Wust P. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: the EORTC 62961-ESHO 95 randomized clinical trial. JAMA Oncol. 2018;4(4):483–492. [PMC free article] [PubMed[]
29. Wittlinger M., Rödel C.M., Weiss C., Krause S.F., Kühn R., Fietkau R. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol. 2009;93(2):358–363. [PubMed[]
30. Yang W.H., Xie J., Lai Z.Y., Yang M.D., Zhang G.H., Li Y. Radiofrequency deep hyperthermia combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Chin Med J (Engl) 2019;132(8):922–927. [PMC free article] [PubMed[]
31. Mitsumori M., Zeng Z.F., Oliynychenko P., Park J.H., Choi I.B., Tatsuzaki H. Regional hyperthermia combined with radiotherapy for locally advanced non-small cell lung cancers: a multi-institutional prospective randomized trial of the International Atomic Energy Agency. Int J Clin Onco. 2007;12(3):192–198. [PubMed[]
32. Ou J., Zhu X., Lu Y., Zhao C., Zhang H., Wang X. The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small cell lung cancer. Eur J Pharm Sci. 2017;109:412–418. [PubMed[]
33. Zafar S.Y., Currow D.C., Cherny N., Strasser F., Fowler R., Abernethy A.P. Consensus-based standards for best supportive care in clinical trials in advanced cancer. Lancet Oncol. 2012;13(2):e77–e82. [PubMed[]
34. Thatcher N., Chang A., Parikh P., Pereira J.R., Ciuleanu T., Von Pawel J. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet. 2005;366(9496):1527–1537. [PubMed[]
35. Chen Q., Espey M.G., Sun A.Y., Lee J.H., Krishna M.C., Shacter E. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A. 2007;104(21):8749–8754. [PMC free article] [PubMed[]
36. Saitoh Y., Yoshimoto T., Kato S., Miwa N. Synergic carcinostatic effects of ascorbic acid and hyperthermia on Ehrlich ascites tumor cell. Exp Oncol. 2015;37(2):94–99. [PubMed[]
37. Lippitz B.E. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–e228. [PubMed[]
38. Silva E.M., Mariano V.S., Pastrez P.R.A., Pinto M.C., Castro A.G., Syrjanen K.J. High systemic IL-6 is associated with worse prognosis in patients with non-small cell lung cancer. PLoS ONE. 2017;12(7):e0181125. [PMC free article] [PubMed[]
39. Tang H., Bai Y., Pan G., Wang X., Wei Y., Yang Z. Interleukin-6 and insulin-like growth factor-1 synergistically promote the progression of NSCLC. Autoimmunity. 2018;51(8):399–407. [PubMed[]
40. Welc S.S., Phillips N.A., Oca-Cossio J., Wallet S.M., Chen D.L., Clanton T.L. Hyperthermia increases interleukin-6 in mouse skeletal muscle. Am J Physiol Cell Physiol. 2012;303(4):C455–C466. [PMC free article] [PubMed[]
41. Chen Y., Luo G., Yuan J., Wang Y., Yang X., Wang X. Vitamin C mitigates oxidative stress and tumor necrosis factor-alpha in severe community-acquired pneumonia and LPS-induced macrophages. Mediators Inflamm. 2014;2014:426740. [PMC free article] [PubMed[]
42. Portugal C.C., Socodato R., Canedo T., Silva C.M., Martins T., Coreixas V.S. Caveolin-1–mediated internalization of the vitamin C transporter SVCT2 in microglia triggers an inflammatory phenotype. Sci. Signal. 2017;10(472) pii: eaal2005. [PubMed[]
43. Marsik C., Kazemi-Shirazi L., Schickbauer T., Winkler S., Joukhadar C., Wagner O.F. C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin Chem. 2008;54(2):343–349. [PubMed[]
44. Mikirova N., Casciari J., Rogers A., Taylor P. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med. 2012;10:189. [PMC free article] [PubMed[]

Articles from Journal of Advanced Research are provided here courtesy of Elsevier

Plaats een reactie ...

Reageer op "Hyperthermie plus hoge dosis vitamine C verbetert overall overleving met 40 procent (9 vs 5 maanden) bij zwaar voorbehandelde met vergevorderde niet-kleincellige longkanker in vergelijking met beste zorg"

Gerelateerde artikelen

Gerelateerde artikelen

Hyperthermie in combinatie >> Matters studie onderzoekt >> Electro hyperthermie naast >> Is de Hyperthermie infra rode >> Hyperthermie plus hoge dosis >> Hyperthermie heeft vaak therapeutisch >> Hyperthermie plus voedingsprogramma >> Hyperthermie studies in overzichtelijk >> Hyperthermie aanvullend op >> Algemeen: een vergelijking >>